FeesSafety
Pluang+

Pfizer's strong Q3 and raised 2026 EPS guidance ease patent expiration fears, keeping it a Buy for investors.

Company Fundamentals
18 Nov 2026, 16:49 WIB
Seeking Alpha
View Source
Bullish
Pfizer's strong Q3 and raised 2026 EPS guidance ease patent expiration fears, keeping it a Buy for investors.

Pfizer Inc. delivered strong Q3 results driven by its oncology portfolio, Eliquis, and tafamidis franchise, with Eliquis revenue growing 25.2% year-over-year to about $2.5 billion. Despite concerns about an upcoming patent expiration cycle lasting around three years, Pfizer raised its 2026 adjusted diluted EPS guidance to $2.95-$3.05 from $2.8-$3. The company’s solid performance and growth prospects have led analysts to maintain a Buy rating on Pfizer stock, highlighting its resilience and potential for long-term investors.

Pfizer shares are trading at USD 28.24 on Pluang as of Nov 18, 2026 22:02 WIB, down 0.77% on the day and below their 52-week high of USD 30.79 but above the 52-week low of USD 23.67. The stock offers a dividend yield of 6.04% and has a market cap of $162.27 billion. Despite the recent price dip, the typical hold time of 158 days suggests steady investor interest in the health sector name.

More News (PFE)

Pfizer beats Q3 revenue estimates, raises 2026 guidance, and shows strong margin growth.

Pfizer beats Q3 revenue estimates, raises 2026 guidance, and shows strong margin growth.

Pfizer reported Q3 revenue of $16.58 billion, exceeding estimates by $700 million, driven by a 32% growth in launched and acquired products and an improved gross margin of about 77%. The company raised its full-year 2026 revenue guidance to $62 billi...

Analyst Insights
Bullish
14 hours ago
Three overlooked dividend stocks now yield over 5%, offering strong income potential with varied risk profiles.

Three overlooked dividend stocks now yield over 5%, offering strong income potential with varied risk profiles.

Three dividend stocks in healthcare, telecom, and financials—Pfizer, Verizon, and OneMain Holdings—currently yield over 5%, attracting income investors seeking high payouts. Pfizer offers a 5.94% yield with growing drug franchises but has tight free ...

Market News
Neutral
1 day ago
Conagra cuts dividend by 50% amid cash flow struggles, signaling market warning on sustainability.

Conagra cuts dividend by 50% amid cash flow struggles, signaling market warning on sustainability.

Conagra Brands cut its quarterly dividend from $0.35 to $0.175 due to negative free cash flow and high leverage, reflecting financial stress. The stock has declined over 38% in five years, showing market skepticism about dividend sustainability witho...

Market News
Bearish
1 day ago
Anti-obesity drug market to hit $64.96B by 2035, led by Eli Lilly and Novo Nordisk with strong new drug launches.

Anti-obesity drug market to hit $64.96B by 2035, led by Eli Lilly and Novo Nordisk with strong new drug launches.

The global anti-obesity drugs market is projected to grow from USD 8.96 billion in 2026 to USD 64.96 billion by 2035, driven by a CAGR of 24.71%. Eli Lilly and Novo Nordisk dominate the market with blockbuster drugs like Mounjaro, Zepbound, and Wegov...

Bullish
2 days ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App